Temeka Stoker, APRN
Primary Care · Fort Worth, TXNPI 1427574458
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 115 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 11.3% — the pattern of someone who eats at a lot of different presentations. Among primary care clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 115 payments — averaging $40.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$523
- AstraZeneca$378
- Teva Pharmaceuticals USA, Inc.$314
- AbbVie$295
- Boehringer Ingelheim$291
- Novo Nordisk$275
- plus $3K from 29 others
What the payments were for
- Food & beverage$4,648100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 5 | $523 |
| AstraZeneca | 16 | $378 |
| Teva Pharmaceuticals USA, Inc. | 3 | $314 |
| AbbVie | 6 | $295 |
| Boehringer Ingelheim | 8 | $291 |
| Novo Nordisk | 10 | $275 |
| Phathom Pharmaceuticals, Inc. | 5 | $256 |
| Lilly USA, LLC | 12 | $194 |
| Abbott | 2 | $178 |
| Sanofi-aventis U.S. LLC | 6 | $175 |
| Amgen | 4 | $151 |
| Boston Scientific | 2 | $141 |
| Neurelis, Inc. | 1 | $125 |
| SK Life Science, Inc. | 1 | $124 |
| Bayer | 2 | $118 |
| Astellas Pharma US Inc | 6 | $111 |
| Alnylam Pharmaceuticals Inc. | 1 | $108 |
| Ultragenyx Pharmaceutical Inc. | 1 | $107 |
| Sumitomo Pharma America, Inc. | 1 | $105 |
| Kowa Pharmaceuticals America, Inc. | 1 | $95 |
| Stemline Therapeutics Inc. | 1 | $83 |
| Edwards Lifesciences | 1 | $81 |
| Medtronic | 1 | $71 |
| Dexcom, Inc. | 3 | $59 |
| Indivior Inc. | 2 | $51 |
| Otsuka America Pharmaceutical, Inc. | 2 | $42 |
| Lundbeck LLC | 3 | $41 |
| Merz North America, Inc. | 2 | $35 |
| Phadia US Inc. | 1 | $24 |
| Globus Medical | 1 | $21 |
| Seqirus USA Inc | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| GSK | 1 | $14 |
| IBSA Pharma Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VOQUEZNA$234
- FREESTYLE LIBRE 3$153
- VALTOCO$125
- XCOPRI$124
- FABRAZYME$122
- CERDELGA$122
- CEREZYME$122
- FARXIGA$120
- JARDIANCE$115
- ArmonAir Digihaler$115
- ProAir Digihaler$115
- AirDuo RespiClick$115
- AUSTEDO$111
- ONPATTRO$108
- CRYSVITA$107
- GEMTESA$105
- KRYSTEXXA$104
- VRAYLAR$104
- LUX-DX$103
How this compares
$4,648 in reported general payments places this provider in the 95th percentile of 563 primary care providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 25 | $29,295 |
| MounjaroTirzepatide | 16 | $16,665 |
| EliquisApixaban | 15 | $15,800 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $8,059 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $6,001 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 14 | $5,778 |
| DapagliflozinDapagliflozin Propanediol | 11 | $5,440 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 13 | $3,552 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $2,585 |
| Febuxostat | 12 | $1,414 |
| Levothyroxine Sodium | 118 | $1,115 |
| Pravastatin Sodium | 97 | $1,094 |
| Rosuvastatin Calcium | 97 | $877 |
| Atorvastatin Calcium | 97 | $869 |
| Gabapentin | 47 | $765 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $275 | $29,29525 claims |
| Lilly USA, LLCMounjaro | $194 | $16,66516 claims |
| GSKBreo Ellipta, Anoro Ellipta | $14 | $14,06033 claims |
| AstraZenecaBevespi Aerosphere, Symbicort | $378 | $8,36325 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 563 primary care providers in Texas.
Other primary care in Fort Worth
- Erika GoffFort Worth$4K
- Mary GibbensHouston$42K
- Phillip GulleySan Antonio$23K
- Herbert BautistaDallas$14K
- Brandi JoynerLongview$12K
- Steven ParisAustin$10K
- Hope OdomCollege Station$10K
- Arlena GraysTomball$9K
- Charlotte BallardSan Antonio$9K
- Hannah LancasterMcKinney$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.